Clinical trial
Comparison of Oral Valganciclovir and Placebo for the Prevention of…
NCT00227370 · Duke University, Other · Completed
Key facts
| NCT number | NCT00227370 |
|---|---|
| Title | Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation |
| Official title | A Phase III, Randomized, Double-Blind Comparison of Oral Valganciclovir and Placebo for Prevention of CMV After Lung Transplantation |
| Acronym | Valgan |
| Lead sponsor | Duke University, Other |
| Collaborators | Roche Pharma AG Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cytomegalovirus Infections |
| Intervention type | Drug, Other |
| Interventions | valganciclovir, Placebo |
| Enrollment | 136 |
| Start date | Jul 1, 2003 |
| Primary completion | Apr 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Sep 28, 2005 |
| Last update posted | Oct 4, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: